Similar results were presented by Ohba et al., who in their observations on 104 patients with glioma showed that contrast enhancement, WHO malignancy, IDH status, and the Ki-67/MIB-1 index influence intraoperative tumor glow assessed by the surgeon [106]. The gene discussed is IDH1; the disease is neoplasm.